| Name | Title | Contact Details |
|---|---|---|
Kieran Byrne |
Executive Director, Ethics and Compliance | Profile |
Fumiaki Sakurai |
Chief Administrative Officer and Chief Ethics and Compliance Officer | Profile |
Katsuyoshi Sugita |
Chief Ethics and Compliance Officer | Profile |
Jim Lynch |
Associate General Counsel | Profile |
Bianca Thomae |
Associate General Counsel | Profile |
Polymed Therapeutics is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Summa Health is one of the largest integrated delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research and multiple foundations, Summa is nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa also is a founding partner of the BioInnovation Institute in Akron. For more information, visit www.summahealth.org. Summa Health is an Affirmative Action employer that promotes Equal Employment Opportunity and Diversity for all individuals. Women, veterans, members of minority groups, and individuals with disabilities are encouraged to apply.
ProUroCare is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Mitsubishi Tanabe Pharma America (MTPA), we believe in helping people who are struggling with serious and debilitating diseases.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.